《新股消息》開拓藥業-B(09939.HK):主要核心產品料下季申請上市 明年投產
開拓藥業-B(09939.HK)首席財務官盧燕表示,用於治療轉移性去勢抵抗性前列腺癌的主要核心藥物「普克魯胺」,快將取得中國臨床試驗結果,預期於第三季提交新藥上市申請(NDA),目標2021年第三季獲批,第四季開始生產並上市。
銷售副總裁嚴明明指,明年首季將為該藥建立150至200人的銷售團隊,憧憬當局對新藥研究的扶持,以及創新藥持續被納納入國家醫保名單,未來計劃將內地團隊擴至300至400人。
另一核心產品「福瑞他恩」將在下半年招募二期臨床試驗首批患者,他透露,該藥用於治療雄激素性脫髮,將建立300人的中國商業化團隊,已與國藥控股(01099.HK)簽署戰略合作協議,未來會探討與其他藥企合作分銷的可能性,並擬與阿里巴巴(09988.HK)及京東等線上藥品平台合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.